An observational study in Isolation of Enterococci From Samples, Demonstration of Enterococci Antibiotic Susceptibility and Detection of Strains Enterococci Produce Biofilm, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 1 Month to 90 Years. Per ClinicalTrials.gov, last updated 2023-04-19.
Sponsored by Sohag University · Observational
Enterococci are Gram-positive facultative anaerobic cocci arranged in short and medium chains. Enterococci reside in the gastrointestinal tract and usually function commensally with humans. They can, however, cause several infections, such as urinary tract infections (UTIs), intra-abdominal infection, bacteremia, or endocarditis.
Among many species identified, E. faecalis and E. faecium are the most common species capable of causing infection and posing a threat of antimicrobial resistance, with E. faecalis accounting for the majority of infections.
Enterococci are Gram-positive facultative anaerobic cocci arranged in short and medium chains.
Enterococci reside in the gastrointestinal tract and usually function commensally with humans. They can, however, cause several infections, such as urinary tract infections (UTIs), intra-abdominal infection, bacteremia, or endocarditis.
Among many species identified, E. faecalis and E. faecium are the most common species capable of causing infection and posing a threat of antimicrobial resistance, with E. faecalis accounting for the majority of infections.
Pathogenic species of enterococci express many virulence factors such as adhesins, gelatinase, Enterococcus surface protein, aggregation substances and cytolysins along with biofilm formation. These factors enhance the ability of the pathogen to invade, attach and survive through the acquisition of nutrients in the host tissue. Their presence in drug resistant strains increases the severity of the infection
Enterococci are intrinsically resistant to antibiotics such as aminoglycosides and β-lactam-based antibiotics. Moderate resistance to aminoglycosides is due to the intrinsic low permeability of the enterococcal cell wall to the large aminoglycoside molecules and is more prevalent in E. faecium than E. faecalis. Intrinsic β-lactam resistance is due to the overexpression of penicillin-binding proteins with low affinity for β-lactams, which makes E. faecalis more resistant to penicillin than E. faecium
Moreover, enterococci can readily acquire resistance to antimicrobials, and vancomycin-resistant enterococci (VRE) are among the priority pathogens for which new antibiotics are needed.
In addition, biofilm formation is one of the strategies for the enterococci to evade the host's immune response and the inhibitory or killing effects of antibiotics.
This self-produced extracellular matrix also provides a suitable microenvironment for enterococci to grow and facilitates the transmission of mobile genetic elements (MGEs) between bacteria. Enterococcal biofilms have been implicated in indwelling device-related infections such as prosthetic valve endocarditis, prosthetic joint infections and catheter-related infections.
Biofilm forming bacteria show resistance to many antibiotics and immune response which results in treatment failure. Given the difficulty of treating and eradicating biofilm associated infections, there is an unmet need for therapeutic options other than antibiotics to prevent biofilm formation.
Nanoparticles are attracting attention given their very small size and various antibacterial properties. Nanoparticles can interact with bacteria per unit area, which can make the antibacterial activity of nanoparticles more powerful. Nanoparticles can also initiate several bactericidal pathways, such as disrupting the bacterial membrane and release of intracellular components, making it difficult for bacteria to become resistant.
141 studies on the registry are indexed under Disease Susceptibility; 31 are open to participants now.
This study's planned enrollment of 100 is below the median of 200 across 84 observational studies indexed under Disease Susceptibility.
Browse Disease Susceptibility studies →Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All the selected patients will be subjected to complete history taking (personal, clinical, associated comorbidities, history of drug intake, and length of hospital stay before sampling).
* Collected samples will be transported to the Medical Microbiology and Immunology research laboratory as soon as possible.
Exclusion Criteria:
Isolates of Enterococci will be identified by Gram staining, colony morphology, catalase test, and growth on Bile Esculin agar. All isolates will be identified to species level using Vitek2 automated system Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on MuellerHinton Agar. The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique Detection of the effect of nanoparticles on the antibiotic susceptibility profile of Enterococci. Detection of the effect of nanoparticles on the biofilm producing Enterococci. Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
Diagnostic Test: Culture · Diagnostic Test: Staining: · Diagnostic Test: Biochemical reactions: · Diagnostic Test: VITEK · Diagnostic Test: Antibiotic sensitivity test · Diagnostic Test: nanoparticles effect · Diagnostic Test: The biofilm formation activity · Diagnostic Test: molecular diagnosis
Diagnostic Test: Culture · Diagnostic Test: Staining: · Diagnostic Test: Biochemical reactions: · Diagnostic Test: VITEK
* Samples will be transported to Medical Microbiology and Immunology Laboratory and will be inoculated on MacConkey medium. * Pink colonies will be inoculated on bile esculin agar medium. * Enterococci produce blackening of the agar
The growing colonies on bile esculin agar medium will be examined microscopically after staining by Gram stain.
* Catalase test. * Salt tolerance test
Automated identification of Enterococci will be done with VITEK2 system.
Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
The effect of nanoparticles on Enterococci antimicrobial resistance pattern
The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using PCR
Isolation and identification of Enterococci from different clinical samples
Isolation and identification of Enterococci from different clinical samples (pus, urine, urinary catheter samples, stool, wound swabs, sputum, central venous catheter samples) will be collected under aseptic precautions from patients admitted at different departments at Sohag university hospitals.
Time frame: from April 2023 to December 2023
Demonstration of Enterococci antibiotic susceptibility profile
Strains confirmed as Enterococci will be examined for their antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller-Hinton Agar.
Time frame: from April 2023 to December 2023
Detection of strains of Enterococci which produce biofilm
The biofilm formation activity of Enterococci isolates will be tested using the microtiter plate technique
Time frame: from April 2023 to December 2023
Studying the effect of nanoparticles on Enterococci antimicrobial resistance pattern
Inhibition zones of all groups will be compared to detect the effect of nanoparticles on Enterococci antimicrobial resistance pattern.
Time frame: from April 2023 to December 2023
Studying the effect of nanoparticles on Enterococci biofilm producing ability
The effect of nanoparticles on Enterococci biofilm producing ability
Time frame: from December 2023 to March 2024
Genotypic characterization of Enterococci.
Molecular identification of some virulence factors genes and antibiotic resistance genes of Enterococci using polymerase chain reaction.
Time frame: rom December 2023 to March 2024
Plan to share: No
This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sohag University